BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19522017)

  • 1. New perspectives in the treatment of advanced or metastatic gastric cancer.
    Rosati G; Ferrara D; Manzione L
    World J Gastroenterol; 2009 Jun; 15(22):2689-92. PubMed ID: 19522017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
    Pozzo C; Barone C
    Oncologist; 2008 Jul; 13(7):794-806. PubMed ID: 18614586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of chemotherapy in metastatic gastric cancer.
    Pasini F; Fraccon AP; DE Manzoni G
    Anticancer Res; 2011 Oct; 31(10):3543-54. PubMed ID: 21965776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
    Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I
    Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in chemotherapy for advanced gastric cancer].
    Xu RH; Teng KY
    Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine for the treatment of advanced gastric cancer.
    Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for advanced gastric cancer.
    Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
    Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Starling N; Rao S; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR;
    N Engl J Med; 2008 Jan; 358(1):36-46. PubMed ID: 18172173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine in the treatment of advanced gastric cancer.
    Lee JL; Kang YK
    Future Oncol; 2008 Apr; 4(2):179-98. PubMed ID: 18407732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
    Roth AD; Fazio N; Stupp R; Falk S; Bernhard J; Saletti P; Köberle D; Borner MM; Rufibach K; Maibach R; Wernli M; Leslie M; Glynne-Jones R; Widmer L; Seymour M; de Braud F;
    J Clin Oncol; 2007 Aug; 25(22):3217-23. PubMed ID: 17664469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment of gastric cancer.
    Dickson JL; Cunningham D
    Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):255-63. PubMed ID: 15195888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review.
    Ohtsu A
    Gastric Cancer; 2005; 8(2):95-102. PubMed ID: 15864716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.
    Duo-Ji MM; Ci-Ren BS; Long ZW; Zhang XH; Luo DL
    Oncotarget; 2017 Jun; 8(23):37896-37911. PubMed ID: 28099947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for advanced gastric cancer.
    Wagner AD; Grothe W; Behl S; Kleber G; Grothey A; Haerting J; Fleig WE
    Cochrane Database Syst Rev; 2005 Apr; (2):CD004064. PubMed ID: 15846694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.